Rigel Pharmaceuticals to Showcase Innovations at Key Healthcare Conference

Rigel Pharmaceuticals to Present at Piper Sandler Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a prominent player in the field of biotechnology, has announced its participation at the upcoming Piper Sandler 37th Annual Healthcare Conference. Set to take place on December 3, 2025, at 8:30 AM ET, Dean Schorno, the company's Chief Financial Officer, will provide a detailed overview of Rigel's ongoing projects and achievements.

This conference represents a significant opportunity for Rigel to highlight its innovative approaches towards developing therapies for hematologic disorders and cancer. As a commercial stage biotechnology company, Rigel caters to the critical needs of patients in these areas by focusing on groundbreaking drug therapies that aim to enhance the quality of life and medical outcomes.

Founded in 1996 and headquartered in South San Francisco, California, Rigel has dedicated itself to the discovery and development of novel therapies. The company’s portfolio includes marketed products and a pipeline full of potential treatments designed to address various hematological challenges, along with oncology applications. Rigel is particularly noted for its quest to uncover insights into molecular and genetic understanding of diseases to formulate targeted therapies.

For those interested in following the presentation, the live webcast will be accessible via Rigel’s Investor Relations section on their official website, www.rigel.com. It is recommended for participants to connect ahead of time to facilitate necessary software downloads for an optimal viewing experience.

As Rigel faces forward, the upcoming healthcare conference will play a pivotal role in informing stakeholders and investors about the company's innovations and future directions. It adds to a series of significant events that have framed Rigel’s progress in the industry, showcasing its commitment to enriching patient lives through tailored biopharmaceutical solutions.

About Rigel
Rigel Pharmaceuticals is dedicated to advancing healthcare through research and development. The company's specific focus areas include developing therapies that address hematologic disorders such as leukemia and other malignancies. This focus is evident in their ongoing research efforts and clinical trials aimed at achieving FDA approvals for their investigational drugs.

For further inquiries or detailed information, media representatives and investors can reach out to Rigel Pharmaceuticals directly at 650.624.1232 or via email at [email protected]
For media inquiries, David Rosen from Argot Partners can be contacted at 646.461.6387 or at [email protected].

In conclusion, Rigel Pharmaceuticals continues to pave the way for advancements in biotechnology with a robust commitment to developing patient-centered treatments. As they gear up for the Piper Sandler Healthcare Conference, anticipation is high for the knowledge and insights they will share regarding their transformative work in the medical field.